U.S. Gas Utilities Stock News

Eva Live, Inc.'s ( NASDAQ:GOAI ) price-to-sales (or "P/S") ratio of 15.3x may look like a poor investment opportunity...

SkyWest, Inc.'s ( NASDAQ:SKYW ) price-to-earnings (or "P/E") ratio of 9x might make it look like a strong buy right now...

Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it saw significant...

What Pediatrix Medical Group’s recent performance tells investors Pediatrix Medical Group (MD) has drawn fresh attention after recent share moves, with the stock up about 19% over the past 3 months but softer over the month and year to date. That mixed pattern, together with its latest financial profile, is prompting investors to reassess how this newborn and pediatric care provider fits into a diversified healthcare portfolio. See our latest analysis for Pediatrix Medical Group. At a share...

If you are wondering whether SLB is priced fairly right now, the stock's recent moves and current valuation metrics give you quite a bit to think about. The share price closed at US$48.87, with returns of 0.7% over the past week, 28.9% over the past month, 21.6% year to date, 23.1% over one year, and a 5.4% decline over three years, while the five year return stands at 125.0%. Recent coverage has focused on SLB as a key name in the energy sector, with investors paying close attention to how...

Wondering if VEON at US$54.07 is offering value or asking too much? This article walks through what the current price might be implying about the company. The stock has been relatively steady over the last week with a 0.1% decline, while the 1 year return of 19.9% and 3 year return of 260.5% sit alongside a 30 day return of 3.0% and year to date return of 2.6%. Recent news coverage has focused on VEON's position as a telecom operator listed on the Nasdaq and on how investors are interpreting...

Context for NIO (NYSE:NIO) after Recent Price Moves NIO (NYSE:NIO) has drawn fresh attention after recent price swings, with the stock showing a 1% decline over the past day and weaker performance over the past month and past 3 months. For investors tracking electric vehicle makers, these moves raise questions about how NIO’s current share price lines up with its fundamentals, recent financial results, and long term business profile in China and abroad. See our latest analysis for NIO. At a...

American Airlines Group (AAL) has wrapped up FY 2025 with Q4 revenue of US$14.0b and basic EPS of US$0.15, alongside net income of US$99m, putting fresh numbers behind a year where trailing 12 month revenue reached US$54.6b and EPS came in at US$0.17. Over the past few quarters, revenue has ranged from US$12.6b to US$14.4b with EPS swinging between a loss of US$0.72 and a profit of US$0.91, while passenger metrics such as an 82.7% Q4 load factor and revenue yield per available seat kilometer...

Key recent performance snapshot Blackbaud (BLKB) has drawn investor attention after recent trading, with the share price at $54.87 and returns showing a 0.3% move over the past day and a small decline over the past week. The stock has recorded deeper negative returns over the past month, past 3 months, year to date, and past year. This may prompt some investors to reassess how its current valuation lines up with the company’s underlying business profile. See our latest analysis for...

In recent days, commentary around Veeva Systems has emphasized its strong balance sheet, high profitability, and leadership in life sciences cloud software, alongside its role in helping consumer goods companies modernize quality and data systems for AI-readiness. An interesting angle is how Veeva is positioning its QualityOne and unified data platforms as foundational tools for companies seeking to operationalize AI while overcoming legacy system and compliance obstacles. Next, we’ll...

FDA label update puts Afrezza dosing in focus for MannKind (MNKD) investors MannKind (MNKD) shares are reacting to the U.S. Food and Drug Administration’s approval of updated prescribing information for Afrezza, clarifying how adults with diabetes can switch from injectable mealtime insulin or pump boluses to the inhaled product. See our latest analysis for MannKind. The FDA label update lands at a time when MannKind’s latest share price sits at US$5.64, with a 90 day share price return of...

In January 2026, IDEXX Laboratories launched the ImageVue DR50 Plus Digital Imaging System and announced major upgrades to its Cancer Dx Panel and inVue Dx analyzer, advancing AI-powered veterinary imaging and in-clinic cancer diagnostics across North America. By pairing lower-radiation, high-definition imaging with earlier and faster canine cancer detection, IDEXX is deepening its role in integrated veterinary care workflows. Next, we examine how IDEXX’s push into AI-enhanced, lower-dose...

W.W. Grainger (GWW) is back in focus after Oppenheimer shifted its rating to Outperform, citing the company’s growth initiatives, pricing power, and use of artificial intelligence, alongside stronger than expected third quarter results. See our latest analysis for W.W. Grainger. Beyond the rating change, W.W. Grainger’s recent news has included a reaffirmed quarterly cash dividend of $2.26 per share and recognition for profitable growth and strong capital efficiency. Meanwhile, the 90 day...

NxtGen AI Pvt Ltd recently announced it has chosen Dell Technologies’ AI Factory with NVIDIA solutions to provide liquid-cooled PowerEdge servers and scalable infrastructure for what is described as India’s largest dedicated AI factory, aimed at supporting generative AI, agentic AI, physical AI and high-performance computing across enterprises, start-ups and government programs. This collaboration underscores Dell’s growing role as a core infrastructure provider for large-scale AI...

The Bancorp, Inc. confirmed it would release its fourth-quarter 2025 results after the market close on January 29, 2026, at 4:00 p.m. Eastern. Investor attention is elevated because analysts expect very strong year-over-year revenue growth while closely watching whether Bancorp rebounds from last quarter’s earnings miss. We will examine how anticipation around Bancorp’s ability to meet revenue expectations is shaping the company’s broader investment narrative. AI is about to change...

If you are wondering whether e.l.f. Beauty shares are offering good value at current levels, the key is to separate story from price and look closely at what the numbers are actually saying. The stock last closed at US$84.98, with returns of 7.0% over the past 30 days, 9.2% year to date, 45.2% over 3 years, 270.4% over 5 years, and a 19.8% decline over the past year. Investors have been reacting to ongoing coverage of e.l.f. Beauty's position in the mass market cosmetics segment and its...

Advanced Micro Devices (AMD) has been drawing fresh attention as investors weigh its recent share performance against its current fundamentals, including US$32.0b in revenue and US$3.1b in net income over the latest reported year. See our latest analysis for Advanced Micro Devices. At a share price of US$252.74, AMD’s recent 17.22% 1 month share price return sits against a slightly negative 90 day move, while a very large 1 year total shareholder return suggests momentum has largely been...

Oppenheimer’s downgrade of Emerson Electric (EMR) from Outperform to Perform has put fresh attention on the stock, as the firm flagged a valuation that already reflects anticipated growth and limits near term upside. See our latest analysis for Emerson Electric. At a share price of US$148.42, Emerson Electric has logged a 9.8% 1 month share price return and 9.3% year to date share price return. Its 1 year total shareholder return of 17.2% and 5 year total shareholder return of 96.8% point to...

If you are wondering whether OneMain Holdings at around US$65.05 is offering fair value or a potential bargain, you are not alone. The stock has had a mixed run, with a 1.6% gain over the last 7 days, a 5.2% decline over 30 days, a 5.8% decline year to date, and a 23.1% return over 1 year, 93.9% over 3 years, and 113.2% over 5 years. Recent coverage has focused on OneMain Holdings as a consumer lender with a focus on personal loans and credit products for non prime borrowers, and on how...

Western Digital has completed the spinoff of its chip-based storage unit, Sandisk, creating a separate entity focused on flash memory products. The company plans to spotlight AI-focused data storage at its upcoming Innovation Day, aimed at addressing growing data needs in cloud and AI workloads. Western Digital, ticker NasdaqGS:WDC, now trades at $279.7, with the stock up 15.6% over the past week and 55.7% over the past month. Year to date, shares are up 49.0%, and over the past 3 years the...

Sterling Infrastructure's E-Infrastructure segment is drawing attention as a key growth driver, with a particular focus on data center projects. The company is being viewed as relatively resilient to concerns around the AI investment cycle, supported by its data center construction activity. Investors are watching how this segment could influence near term sentiment toward NasdaqGS:STRL. Sterling Infrastructure, trading on NasdaqGS:STRL, is increasingly being evaluated through the lens of...

Dynatrace (DT) is back in focus after its Perform 2026 user conference, where management introduced Dynatrace Intelligence, expanded cloud integrations, and new real user monitoring tools for complex, AI driven multi cloud environments. See our latest analysis for Dynatrace. Despite the Perform 2026 announcements, Dynatrace shares at US$40.65 reflect a 30 day share price return of an 8% decline and a 90 day share price return of a 16% decline. The 1 year total shareholder return of a 29%...

The recent proposal from the Centers for Medicare & Medicaid Services for 2027 Medicare Advantage payment updates, which signals only modest payment growth, has become a key focus for Astrana Health (ASTH) shareholders after triggering a sharp price reaction. See our latest analysis for Astrana Health. The CMS proposal has come on top of what has already been a weak stretch for Astrana Health, with a 7 day share price return of a 17.54% decline, a 90 day share price return of a 30.84% decline...

Earlier this week, Sarepta Therapeutics reported three-year topline results from its Phase 3 EMBARK trial showing ELEVIDYS produced statistically significant, durable improvements in motor function for ambulatory children with Duchenne muscular dystrophy, with no new safety signals observed. A key insight from EMBARK is that ELEVIDYS-treated patients maintained motor abilities above baseline while comparable untreated patients followed the expected age-related decline, underscoring a...